Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include Tuberculosis Research and Epidemiology, Mycobacterium research and diagnosis, Infectious Diseases and Tuberculosis, and Diagnosis and treatment of tuberculosis.
A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis
Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study
Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy
Clinical standards for antimicrobial stewardship in TB care
Tuberculosis in adult migrants in Europe: a TBnet consensus statement
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe
Impact of the COVID-19 pandemic on the real-world diagnostic infrastructure for tuberculosis—An ESGMYC collaborative study
Recent advances in the treatment of tuberculosis
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement
Standards for clinical trials for treating TB
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases
Availability and costs of medicines for the treatment of tuberculosis in Europe
Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment
Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study
Evidence-based Definition for Extensively Drug-Resistant Tuberculosis
TB research requires strong protections, innovation, and increased funding in response to COVID-19
Use and impact of molecular methods for detecting drug‐resistant TB
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
Bedaquiline and Delamanid for Drug-Resistant Tuberculosis: A Clinician’s Perspective
Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB
The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement
QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study
Safety and efficacy of exposure to bedaquiline−delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis